Herald Investment Management’s Vertex VERX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-300,000
Closed -$3.44M – 82
2026
Q2
$3.44M Buy
300,000
+100,000
+50% +$1.25M 0.47% 66
2026
Q1
$2.37M Hold
200,000
– – 0.33% 71
2025
Q4
$3.99M Hold
200,000
– – 0.52% 57
2025
Q3
$4.96M Buy
200,000
+90,000
+82% +$2.61M 0.66% 42
2025
Q2
$3.89M Hold
110,000
– – 0.58% 49
2025
Q1
$3.85M Sell
110,000
-10,000
-8% -$457K 0.72% 36
2024
Q4
$6.41M Hold
120,000
– – 1.05% 30
2024
Q3
$4.62M Hold
120,000
– – 0.8% 37
2024
Q2
$4.33M Hold
120,000
– – 0.71% 40
2024
Q1
$3.81M Hold
120,000
– – 0.62% 43
2023
Q4
$3.23M Sell
120,000
-30,000
-20% -$769K 0.62% 42
2023
Q3
$3.46M Hold
150,000
– – 0.74% 34
2023
Q2
$2.92M Hold
150,000
– – 0.57% 48
2023
Q1
$3.1M Hold
150,000
– – 0.69% 45
2022
Q4
$2.18M Hold
150,000
– – 0.53% 58
2022
Q3
$2.05M Hold
150,000
– – 0.51% 60
2022
Q2
$1.7M Hold
150,000
– – 0.39% 72
2022
Q1
$2.29M Hold
150,000
– – 0.42% 69
2021
Q4
$2.38M Hold
150,000
– – 0.39% 74
2021
Q3
$2.87M Buy
+150,000
New +$2.9M 0.47% 64

Other funds holding VERX

Herald Investment Management's VERX Position: Q3 2026 in Review

Herald Investment Management sold out of Vertex (VERX) in Q3 2026, closing a stake of 300,000 shares — an estimated $3.44M sold.

Herald Investment Management first reported a position in VERX in Q3 2021 and held it in 20 quarters. The position peaked at $6.41M in Q4 2024. 8 funds tracked by Wall St. Rank hold VERX as of Q3 2026.

  • Herald Investment Management reported no remaining Vertex position as of Q3 2026 after selling out during the quarter.
  • Herald Investment Management sold 300,000 Vertex shares in Q3 2026, an estimated $3.44M.
  • Herald Investment Management first reported a position in Vertex in Q3 2021 and held it in 20 quarters.
  • Herald Investment Management's Vertex position peaked at $6.41M in Q4 2024.
  • 8 funds tracked by Wall St. Rank held Vertex as of Q3 2026.

Based on Herald Investment Management's 13F filing for Q3 2026.